This trial is testing GSK2857916 combined with Pembrolizumab in patients with relapsed/refractory myeloma. Researchers are studying whether these drugs work in myeloma, are safe, and what doses work best.
This trial is currently open and accepting patients.
This trial is being run in two parts. Part 1 has completed and Part 2 is now open and accepting patients.
This trial is non-randomized, and sequentially assigned, which means that the group you are placed in, and dose of the study drugs you receive will be determined by when you join the study.
This trial is open label, which means that both you and the researchers running the study will know which group you are placed in, and the dose of the study drugs you are receiving.
Enrollment: 40 patients (estimated)View More
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.
View all clinical trial locations sorted by state.
Read the latest news and updates on this trial.
January 21, 2020
March 21, 2019
Median progression-free survival extends to twelve months
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message